Products
« APTIMA COMBO 2® Assay
« APTIMA® CT Assay
« APTIMA® GC Assay
« APTIMA® HPV Assay
« APTIMA® HCV RNA Qualitative Assay
« APTIMA® HIV-1 RNA Qualitative Assay
« PROGENSA® PCA3 Assay
Products Line « Molecular Biology « TMA Assays
Print Page Print
PROGENSA® PCA3 Assay
Description

The PCA3 Assay is a simple test: following a digital rectal examination (DRE), cancerous cells with high levels of PCA3 are shed from the prostate into the urine. A urine sample is then collected. This urine sample is sent to a laboratory to determine the PCA3 Score. A high PCA3 Score indicates an increased likelihood of a positive biopsy, i.e. presence of cancer cells in the prostate. A low PCA3 Score indicates a decreased likelihood of a positive biopsy. If the PCA3 Score is low, a biopsy may be delayed or eventually avoided. In this way, the PCA3 Assay may help to avoid many unnecessary first biopsies and the potential discomfort and complications (pain, bleeding and infections) for the men involved.The PCA3 Assay can also be used in men with one or more previous negative biopsies to predict the likelihood that another biopsy will be positive, or to assess the need for a next biopsy.
 

logo logo logo logo logo
About Us | Product Lines WiseGroup Website Development